Shares of HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $13.89, but opened at $15.12. HUTCHMED shares last traded at $15.40, with a volume of 4,000 shares trading hands.
Analyst Upgrades and Downgrades
Separately, StockNews.com upgraded HUTCHMED from a "hold" rating to a "buy" rating in a research report on Friday, March 21st.
Check Out Our Latest Stock Report on HUTCHMED
HUTCHMED Stock Down 7.2 %
The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The firm has a 50-day simple moving average of $14.96 and a 200 day simple moving average of $15.78.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC boosted its stake in HUTCHMED by 362.2% in the 3rd quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock worth $1,305,000 after purchasing an additional 49,366 shares in the last quarter. State Street Corp lifted its stake in shares of HUTCHMED by 0.9% in the third quarter. State Street Corp now owns 349,524 shares of the company's stock worth $6,826,000 after buying an additional 3,078 shares in the last quarter. ABC Arbitrage SA purchased a new stake in shares of HUTCHMED during the fourth quarter valued at approximately $500,000. XY Capital Ltd bought a new stake in shares of HUTCHMED during the fourth quarter valued at approximately $673,000. Finally, Crossmark Global Holdings Inc. raised its holdings in HUTCHMED by 10.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock worth $268,000 after acquiring an additional 1,799 shares during the last quarter. Hedge funds and other institutional investors own 8.82% of the company's stock.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Further Reading
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
